This week, major employer Cambrex in Charles City announced that it is expanding its mid-scale and large-scale API manufacturing capacity. This will be a $50+ million investment designed to meet the continually growing demand for small molecule drug substance development and manufacturing.
The expansion, which will be operational in early 2022, will add 3 large-scale manufacturing work centers and 1 mid-scale work center to the facility in Iowa, increasing the site’s capacity by 30 percent. When completed, the Charles City site will employ more than 400 people.
President of Cambrex’s Drug Substance Business Unit Joe Nettleton says:
“Small molecule manufacturing demand has been growing consistently over recent years, and this investment will enable Cambrex to continue to capitalize on this growth, further strengthening our position as a market-leading CDMO.”
In 2019, Cambrex was acquired by funds advised by Permira, a global investment firm, to continue to build upon Cambrex’s market leading position in API development and manufacturing and support the growth of its integrated service offering across the pharmaceutical value chain.